Aurora Fine Chemicals is a privately held company that was founded in 1990. As a chemicals R&D supplier we offer chemicals for R&D, drug discovery service, compound libraries and custom synthesis. We have one of the largest collections of 18.1 mln. chemicals available in stock and our docking software delivers hits/leads of very high quality in short time.
Our staff consists of highly qualified individuals with Bsc, Msc and Ph.D. degrees in chemistry, as well as excellent laboratory technicians. In our Molecular Modeling Group are professionals specializing in computational drug design. They possess many years experience of working in the chemistry of heterocycles, carbohydrates, nucleosides and elemental organic compounds. Aurora has significant expertise in synthesis of all types R&D chemicals for drug discovery like small molecules, natural products and peptides. Parallel synthesis with well-designed, targeted and fragment-based libraries is the favored approach to lead optimization. Rational design is the strategy for projects driven by structural biology, such as enzyme inhibitors or protein interactions.
We own a large library of 18.1 million stocked compounds for R&D. Our substances are used in many research labs all over the world. We offer structures for biochemical and chemical research. Our products are applied in pharmaceutical development, diagnosis, and in chemical production.
Several laboratories for synthesis with modern equipment such as reactors, autoclaves, thermostats and hydrogenation equipment are available.
Intermediates and final products are analyzed by GC, HPLC, IR, NMR, MS, elemental analysis, atom-absorption analysis and crystallographical methods.
The main advantage of Aurora's own software is the quality of the underlying physical models. Aurora's software derives molecular properties from first principles based on direct models using advanced quantum mechanical analysis of molecular interactions and thermodynamics.
Biopolis, S.L. is a leading microbial biotechnology company based in Valencia (Spain) offering Contract Research and Manufacturing. Our core competences are the isolation, selection, design, characterization, validation and production of microorganisms and cellular metabolites with applications in agrifood, feed, pharmaceutical, chemical and environment industries.
As Tailor-made Biotechnological company, we develop solutions for our clients even if Biopolis has internal R&D research lines.
Prototype projects (i) the selection, validation and production of functional probiotics and starters, (ii) the identification, characterization and process development of functional ingredients, (iii) the overexpression of recombinant protein in microbial systems, (iv) the overproduction of synthesis intermediates and active pharmaceutical ingredients (v) the design of novel processes based on microbial and enzymatic catalysis for bulk chemical production (vi) the selection and production of enzymes and (vii) the revaluation of waste and by-products of industry.
Biopolis facilities spread over 1500 m2, hosting 9 specialized research laboratories distributed in 3 Departments (Agri-food Biotechnology, Microbian Biotechnology and Production capacity of 9000 L fermentation).
We offer omics technologies (transcriptomics, metabolomics, and metagenomics) to guarantee a complete service to our customers.
Pharmatory Ltd. is a Finnish cGMP custom synthesis provider for pharmaceutical companies. Pharmatory specialises in custom process R&D, scale-up and cGMP manufacturing of key intermediates and active pharmaceutical ingredients with focus on quality operation and timely delivery.
We offer following services:
- Custom synthesis and development of APIs and key intermediates
- Process research and development, scale-up and optimization
- cGMP manufacturing (scale from milligrams up to tens of kilograms)
- Biocatalysis services
- Preparation of reference materials
- Preparation of isotope labeled substances
- Stability testing, impurity profiling
- Development and validation of analytical methods
Takara Bio Europe is a member of the Takara Bio Group, a leading supplier of tools for life scientists worldwide. We serve customers in a wide range of scientific settings, including academic institutions, government research facilities, clinical research, and pharmaceuticals in Europe, Middle East and Africa.
We are a dynamic team of professionals, all dedicated to providing best-in-class solutions to research scientists in advanced biology. Quality, efficiency and the care of our customers, suppliers and staff are paramount to the way we work.
With offices in Paris, France and Göteborg, Sweden, Takara Bio Europe is an outstanding place to work offering the unique opportunity to take an independent position within a European organization.
We are always looking for skilled and motivated professionals.
We strive to deliver innovative technologies that help push every experiment to its fullest potential. Through our brand names TAKARA®, CLONTECH® and CELLARTIS™ we develop innovative technologies in the fields of Cell Biology, Molecular Biology, Proteomics and Stem Cell Research.
Key products include SMART cDNA synthesis kits, including NGS, high-performance qPCR and PCR reagents, Cellartis stem cells and stem cell reagents, RT enzymes and SMART library construction kits, the innovative In-Fusion® cloning system, Guide-it gene editing tools, Tet-based inducible gene expression systems, and Living Colors® fluorescent proteins.
Recently, Takara Bio acquired Rubicon Genomics and WaferGen Bio-systems. As part of the Takara Bio family, they expand our NGS portfolio as well as add R&D, manufacturing, and support for automation systems for NGS and qPCR applications. Takara Bio’s portfolio supports applications including NGS, gene discovery, regulation, and function studies, as well as genetic analysis, protein expression and purification, gene editing, stem cell studies, and plant and food research. For more information, visit takarabio.com.
ADC Biotechnology Ltd was founded in 2010 to develop and commercialise next generation conjugation technologies to the Antibody Drug Conjugate market. Bioconjugation using our proprietary 'Lock-Release' technology involves conjugation of proteins that are immobilised on solid supports, which delivers a number of key product advantages from minimal aggregate formation to minimal residual free drug and enhanced yields. From basic R&D applications through to improved supply economics and product risk management application of our 'Lock-Release' platform drives value through better products delivered with greater efficiency.
In addition to technology development, ADC Biotechnology offers a range of technical services, including conjugation (conventional and Lock-Release) to a variety of toxin payloads, toxin-linker design and synthesis and supply of ADCs for proof of concept and toxicology testing.
For more information on our services and Lock Release please visit